Latest News for ESALF
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
NUTLEY, N.J., April 9, 2026 /PRNewswire/ -- Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 2026 American Academy of Neurology (AAN) Annual Meeting from April 18-22 in Chicago and online.
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working
STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US Leqembi was approved in Brazil and Canada Leqembi was approved for IV maintenance treatment in the United Kingdom Eisai submitted…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ESALF.
Senate Trading
No Senate trades found for ESALF.
U.S. House Trading
No House trades found for ESALF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.